Evidence map›Paper›PMID 36257060›Full record

ArticleJournal of medicinal chemistry2022

Structure-Uptake Relationship Studies of Oxazolidinones in Gram-Negative ESKAPE Pathogens.

Ziwei Hu, Inga V Leus, Brinda Chandar, Bradley S Sherborne, Quentin P Avila, Valentin V Rybenkov, Helen I Zgurskaya, Adam S Duerfeldt

Erratum issuedOpen access · greenAbstract read
In one paragraph

Article in Journal of medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Synthesis and Fluorescence Profiling of Naphthylamine Analogs.Chembiochem : a European journal of chemical biology · 2026
    Article
  2. Article
  3. No two are alike: on the role ofAntimicrobial agents and chemotherapy · 2025
    Article
  4. The Journal of organic chemistry · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ziwei HuDepartment of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55414, United States.
Inga V LeusDepartment of Chemistry & Biochemistry, University of Oklahoma, Stephenson Life Sciences Research Center, Norman, Oklahoma 73019, United States.
Brinda ChandarDepartment of Chemistry & Biochemistry, University of Oklahoma, Stephenson Life Sciences Research Center, Norman, Oklahoma 73019, United States.
Bradley S SherborneMerck & Co., Inc., Rahway, New Jersey 07065, United States.ORCID 0000-0002-0037-3427
Quentin P AvilaDepartment of Chemistry & Biochemistry, University of Oklahoma, Stephenson Life Sciences Research Center, Norman, Oklahoma 73019, United States.
Valentin V RybenkovDepartment of Chemistry & Biochemistry, University of Oklahoma, Stephenson Life Sciences Research Center, Norman, Oklahoma 73019, United States.ORCID 0000-0002-5300-4369
Helen I ZgurskayaDepartment of Chemistry & Biochemistry, University of Oklahoma, Stephenson Life Sciences Research Center, Norman, Oklahoma 73019, United States.ORCID 0000-0001-8929-4727
Adam S DuerfeldtDepartment of Medicinal Chemistry, College of Pharmacy, University of Minnesota, Minneapolis, Minnesota 55414, United States.ORCID 0000-0002-3130-9890
University of Oklahoma · USUniversity of Minnesota · USMerck & Co., Inc., Rahway, NJ, USA (United States) · US

Funding

Predictive Models for Small-Molecule Accumulation in Gram-Negative BacteriaR01AI136795 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI TAN, DEREK S, ZGURSKAYA, HELEN I · 2018 to 2022
$6.5M
Optimization of efflux avoidance and inhibition for antibiotic developmentR01AI136799 · NIAID · UNIVERSITY OF OKLAHOMA · PI GNANAKARAN, SANDRASEGARAM, RUGGERONE, PAOLO · 2018 to 2022
$5.7M
Permeability Barriers of Gram-negative Pathogens and Approaches to Bypass ThemR01AI132836 · NIAID · UNIVERSITY OF OKLAHOMA · PI HELEN I ZGURSKAYA · 2017 to 2026
$4.3M
NIAID NIH HHS R01 AI132836NIAID NIH HHS R01 AI136795NIAID NIH HHS R01 AI136799
6 · The paper itself

Abstract

The clinical success of linezolid for treating Gram-positive infections paired with the high conservation of bacterial ribosomes predicts that if oxazolidinones were engineered to accumulate in Gram-negative bacteria, then this pharmacological class would find broad utility in eradicating infections. Here, we report an investigative study of a strategically designed library of oxazolidinones to determine the effects of molecular structure on accumulation and biological activity.

Indexed as

OxazolidinonesAnti-Bacterial AgentsEscherichia coliGram-Negative BacteriaLinezolidMicrobial Sensitivity TestsAnti-Bacterial AgentsLinezolidOxazolidinones

Identifiers

PMID36257060
PMCPMC9942527
OpenAlexW4306721378

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.